The maker of Ozempic and Wegovy is suing a rival firm for selling what it says are unsafe, knock-off versions of its weight-loss drugs in the US. Danish company Novo Nordisk asked US courts on Monday to ban Hims & Hers' range of weight-loss pills and injections, which it says are not approved by US authorities and infringe on its patent. The legal drama began on Friday after Hims & Hers launched a new weight-loss pill, leading to an initial threat from Novo Nordisk. Over the weekend, Hims & Hers said it would stop selling the pill. On Monday, its share price slumped as it called Novo Nordisk's decision to press ahead with the lawsuit a blatant attack.

Record cold for 235 million Americans starting in just HOURS as polar vortex brings'most extreme cold on Earth' Is this the END of Ozempic? Nashville neighbors can see what's REALLY going on with Nicole Kidman. Even I was once overweight. So trust me, this 30 DAY detox plan will get you thin WITHOUT Ozempic... but if you want to stay skinny, you'll have to make one major sacrifice: JILLIAN MICHAELS Mom who spent 10 years'gentle parenting' admits it was a mistake: 'My kids are anxious, insecure and entitled' Worrying side-effect of creatine you aren't being warned about: Cheap supplement is hailed as a'miracle' - but here's how to tell if YOUR brand is doing more harm than good Amazon warns 300 million shoppers of Cyber Monday scam... and how to avoid it'Murder for hire' housewife begs Bahamas judge to free her from GPS shackles so she can start a shocking new career Trump suffers fresh legal blow as Alina Habba's disqualification is upheld by appeals court Trump sparks fury as he frees $1.6 BILLION fraudster just days into seven-year-sentence I was drinking 130 units of alcohol a week and knew it was time to cut down. Then, I discovered this no-effort miracle solution.

What we still don't know about weight-loss drugs Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind Mounjaro and Zepbound, became the first healthcare company in the world to achieve a trillion-dollar valuation. But we also learned that, disappointingly, GLP-1 drugs don't seem to help people with Alzheimer's disease. And that people who stop taking the drugs when they become pregnant can experience potentially dangerous levels of weight gain. On top of that, some researchers worry that people are using the drugs postpartum to lose pregnancy weight without understanding potential risks. All of this news should serve as a reminder that there's a lot we still don't know about these drugs.

A viral video of a colony of bunnies seemingly enjoying jumping on a trampoline, posted in July, had more than 200m views - but was identified as AI-generated. A viral video of a colony of bunnies seemingly enjoying jumping on a trampoline, posted in July, had more than 200m views - but was identified as AI-generated. Macquarie Dictionary announces'AI slop' as its word of the year, beating out Ozempic face AI slop is here, it's ubiquitous, it's being used by the US president, Donald Trump, and now, it's the word of the year. The Macquarie Dictionary dubbed the term the epitome of 2025 linguistics, with a committee of word experts saying the outcome embodies the word of the year's general theme of reflecting "a major aspect of society or societal change throughout the year". "We understand now in 2025 what we mean by slop - AI generated slop, which lacks meaningful content or use," the committee said in a statement announcing its decision.

Eli Lilly's experimental obesity drug works differently than Ozempic and Wegovy, targeting amylin receptors for significant weight loss in a recent study.

Models Dee O (left) and Danielle Mareka at the Everyman bar in King's Cross, London. Models Dee O (left) and Danielle Mareka at the Everyman bar in King's Cross, London. 'You definitely felt disposable': models - one 27, one 62 - discuss Botox, weight loss, creativity and the threat of AI Modelling has changed hugely over the decades. I t's easy to think of models as people whose lives are full of glitz and glamour, who "don't wake up for less than $10,000 a day". But according to New York-based Danielle Mareka, 27, and 62-year-old Dee O, who lives in London, the reality for most models is a constant hustle to get noticed.

Work done during internship at Meta AI. 38th Conference on Neural Information Processing Systems (NeurIPS 2024).

After losing nearly six stone since December with the help of weight-loss injections, Emilly Murray has been left with an unwanted reminder of her former body - loose skin. I can't wear what I want to wear, says the 35-year-old from Liverpool. I cannot get my legs out because the skin hangs over my knee so much. While she doesn't regret losing weight for the benefit of her health, Emilly says the loose skin on her thighs really does get me down as it makes her feel self-conscious, and the way she looks naked makes her feel like a catfish. It looks okay when it's all pulled in, but then I feel like, when I take my clothes off, I look like a 90-year-old woman.

While bariatric and metabolic surgery (MBS) is considered the gold standard treatment for severe and morbid obesity, its therapeutic efficacy hinges upon active and longitudinal engagement with multidisciplinary providers, including surgeons, dietitians/nutritionists, psychologists, and endocrinologists. This engagement spans the entire patient journey, from preoperative preparation to long-term postoperative management. However, this process is often hindered by numerous healthcare disparities, such as logistical and access barriers, which impair easy patient access to timely, evidence-based, clinician-endorsed information. To address these gaps, we introduce bRAGgen, a novel adaptive retrieval-augmented generation (RAG)-based model that autonomously integrates real-time medical evidence when response confidence dips below dynamic thresholds. This self-updating architecture ensures that responses remain current and accurate, reducing the risk of misinformation. Additionally, we present bRAGq, a curated dataset of 1,302 bariatric surgery--related questions, validated by an expert bariatric surgeon. bRAGq constitutes the first large-scale, domain-specific benchmark for comprehensive MBS care. In a two-phase evaluation, bRAGgen is benchmarked against state-of-the-art models using both large language model (LLM)--based metrics and expert surgeon review. Across all evaluation dimensions, bRAGgen demonstrates substantially superior performance in generating clinically accurate and relevant responses.